fashion -WSS

fashion

author：leisure time 2025-09-05 13:32:44 - browse：33555

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： How to make Best Hospitals ratings actually useful for patients

focus

explore

WSS

Maui funeral service workers on devastation of fires: 'I'm in shock'

Psilocybin's anti

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Large hospital system sues Multiplan for low

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

CDC overhauls leadership of center that led response to Covid

focus

fashion

focus

Wildfire smoke exposes gaps in outdoor worker protections

Kim Kardashian sparks debate on benefits of full

Heart attack and stroke risk calculators need revising

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Medicare proposal to cover medical devices draws a mixed reaction

TB outbreak tied to bone grafts underscores testing shortcomings

Medical leaders decry Supreme Court decision on affirmative action

What AAP's gender

Medicare details structure of new drug price negotiation program

Study finds new variant for Parkinson’s in African populations

hotspot

In science, is the line between industry and academia shifting?

Novo acquires Inversago for up to $1 billion

AstraZeneca challenges Medicare drug negotiation program

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Pharma budget tightening trickles down to Doximity

NYU Langone launches private ChatGPT for its health care data

focus

focus

explore

focus